P5-13-19: Borderline Estrogen and Progesterone Receptor Expr…
Emerging
0
Citations0
Refs2011
Year
Search Works
Work Details
- DOI 10.1158/0008-5472.sabcs11-p5-13-19
- OpenAlex ID W2332865114
- Type Article
- Language EN
- Published 01 Dec 2011
- Volume 71 (24_Supplement)
- Pages P5–13
- Source Cancer Research
- Publisher American Association for Cancer Res…
- Countries 1
- Institutions 2
- Added 10 Oct 2025
- Updated 01 Oct 2026
External Links
MENU
0
P5-13-19: Borderline Estrogen and Progesterone Receptor Expression and Efficacy of Anti-Estrogen Therapy Analyzed by Subpopulation Treatment Effect Pattern Plot Analysis.
Article 2011 EN
Abstract Background: The American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) recently recommended that estrogen receptor (ER) and progesterone receptor (PR) values be considered positive in the evaluation of breast cancer specimens if there are at least 1% positive tumor nuclei by immunohistochemisty (IHC) scoring. This change constitutes a lower cutoff valu…
0
Citations
0
References
4
Authors
0.00
FWCI
Topics
Keywords
UN Sustainable Development Goals
1 SDGsAuthors & Affiliations
4 authors| # | Author | Institutions | ORCID |
|---|---|---|---|
| 1 | S-W Luoh | Oregon Health & Science Univer… (US) Portland VA Medical Center (US) | — |
| 2 | Betsy Ramsey | Oregon Health & Science Univer… (US) Portland VA Medical Center (US) | — |
| 3 | Bombi Park | Oregon Health & Science Univer… (US) Portland VA Medical Center (US) | |
| 4 | Edward J. Keenan | Oregon Health & Science Univer… (US) Portland VA Medical Center (US) | — |
Related Works
10Data: OpenAlex